Pharmaceutical Executive Daily: Eli Lilly Acquires Kelonia Therapeutics

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Eli Lilly enters a $7 billion agreement to acquire Kelonia Therapeutics, the Trump administration issues an executive order to accelerate FDA reviews of psychedelic therapies, and Lilly’s oral weight loss pill sees strong early prescribing demand.

Eli Lilly and Company has entered a $7 billion agreement to acquire Kelonia Therapeutics, expanding its presence in genetic medicine and delivery platforms. The acquisition reflects Lilly’s broader strategy to invest in next-generation technologies that can complement its existing pipeline and drive long-term innovation across multiple therapeutic areas.

In Washington, Donald Trump has issued an executive order aimed at accelerating U.S. Food and Drug Administration reviews of psychedelic therapies for mental health conditions. The policy shift signals growing federal attention on emerging treatment modalities, while raising questions around regulatory standards, evidentiary thresholds, and how quickly such therapies could reach patients.

Finally, Eli Lilly and Company’s oral weight loss pill is seeing strong early uptake, with roughly 13,900 prescriptions reported in its first days on the market. The early demand highlights continued momentum in the obesity treatment space and suggests increasing acceptance of oral GLP-1 therapies as a convenient alternative to injectable options.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.